Dr. Cinamon has a vast experience in leading early stage drug development. After a post-doctorate fellowship at the University of California, San Francisco, Dr. Cinamon joined Teva Pharmaceutical Industries where he was a Director and held a Project Champion position. In this role he led many early stage projects of both auto-immune and cancer related indications, overseeing all aspects of drug development. He next moved to Quiet Therapeutics, where he held a position of VP Pre-Clinical Development & GM, leading the development of a targeted drug against cancer, based on nanoparticles. Dr. Cinamon received his Ph.D. in Immunology from the Weizmann Institute of Science.